Last reviewed · How we verify
Aspirin and indobufen mimetic — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Aspirin and indobufen mimetic (Aspirin and indobufen mimetic) — Beijing Anzhen Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Aspirin and indobufen mimetic TARGET | Aspirin and indobufen mimetic | Beijing Anzhen Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Aspirin and indobufen mimetic CI watch — RSS
- Aspirin and indobufen mimetic CI watch — Atom
- Aspirin and indobufen mimetic CI watch — JSON
- Aspirin and indobufen mimetic alone — RSS
Cite this brief
Drug Landscape (2026). Aspirin and indobufen mimetic — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-and-indobufen-mimetic. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab